- Max Healthcare’s net income for the third quarter declined by 17% year-on-year, amounting to 2.39 billion rupees versus the estimated 3.62 billion rupees.
- Revenue increased by 41% year-on-year, reaching 18.7 billion rupees, but this fell short of the estimated 21.74 billion rupees.
- Total costs rose significantly, by 49% year-on-year, totaling 15.2 billion rupees.
- Operational EBITDA saw a 32% year-on-year increase, standing at 6.22 billion rupees.
- The company has approved an investment of 1.25 billion rupees in Jaypee Healthcare.
- A pact is in place to lease a 500-bed hospital in Thane.
- Max Healthcare has approved issuing a corporate guarantee to Yes Bank for a term loan up to 5 billion rupees for Nirogi Charitable and Medical Research Trust to establish a 400-bed hospital in Delhi.
- The company is set to provide up to 2 billion rupees of financial assistance to Eqova Healthcare to meet obligations under a medical services agreement for a hospital in Delhi.
- The board has approved securing a term loan of up to 5 billion rupees from Axis Bank to partially finance the construction of a hospital in Gurugram.
- Analyst recommendations for the company are divided as follows: 13 buys, 3 holds, and 5 sells.
Max Healthcare Institute on Smartkarma
Analyst coverage on Smartkarma reveals insightful research on Max Healthcare Institute by Tina Banerjee. In a bullish stance, the report titled “Max Healthcare (MAXHEALTH IN): Continues to Strengthen Presence in North India” discusses Max Healthcare’s acquisition of a controlling stake in Jaypee Healthcare. This move includes acquiring three hospitals in Uttar Pradesh, notably the esteemed 500-beds Jaypee Hospital, Noida. The valuation of the deal appears reasonable, with JHL reporting substantial revenue and EBITDA figures in FY24. The acquisition is projected to significantly bolster Max Healthcare’s network and reinforce its leading position in the NCR, an area inhabited by approximately 46 million individuals.
A look at Max Healthcare Institute Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Max Healthcare Institute is positioned for long-term growth and resilience in the healthcare industry. With a strong momentum score of 5, the company shows promising upward trends. This indicates a positive outlook for future performance. Additionally, scoring high in growth and resilience at 4, Max Healthcare Institute is expected to continue expanding and adapting to market challenges, showcasing its ability to withstand uncertainties.
Despite having average scores in value and dividend at 2, the overall high scores in growth, resilience, and momentum suggest that Max Healthcare Institute is well-positioned to thrive in the long term. With a diverse range of services including urology, oncology, and orthopaedics among others, the company serves a wide range of patients in India, showcasing potential for further development and success in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
